Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic
- 12 December 2016
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 36 (21) , 3037-3047
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.Keywords
This publication has 63 references indexed in Scilit:
- Flow Cytometric Quantification of All Phases of the Cell Cycle and Apoptosis in a Two-Color Fluorescence PlotPLOS ONE, 2013
- Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processesJournal of Clinical Investigation, 2012
- Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast CancerClinical Cancer Research, 2011
- eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progressionProceedings of the National Academy of Sciences, 2010
- Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?Leukemia & Lymphoma, 2010
- Use of the Ki67 promoter to label cell cycle entry in living cellsCytometry Part A, 2010
- Endothelial deletion of hypoxia-inducible factor–2α (HIF-2α) alters vascular function and tumor angiogenesisBlood, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Inhibition of 4E-BP1 Sensitizes U87 Glioblastoma Xenograft Tumors to Irradiation by Decreasing Hypoxia ToleranceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005